Patiromer

DRUG17 trials

Sponsors

Vifor Pharma, Inc., Relypsa, Inc., NYU Langone Health, The Rogosin Institute, Dominic Raj

Conditions

Acute HyperkalemiaChronic Kidney DiseaseChronic Kidney Disease (CKD)Chronic Kidney DiseasesESRDEnd Stage Renal DiseaseHeart FailureHeart Failure，Congestive

Phase 2

Evaluation of Patiromer in Heart Failure Patients

CompletedNCT00868439

Relypsa, Inc.Heart Failure, Hyperkalemia

Start: 2009-04-30End: 2009-12-31Updated: 2021-06-02

Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease

CompletedNCT01130597

Relypsa, Inc.Heart Failure

Start: 2010-05-31End: 2010-09-30Updated: 2021-05-12

Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)

CompletedNCT01371747

Relypsa, Inc.Chronic Kidney Disease, Hyperkalemia, Hypertension

Start: 2011-06-30End: 2013-06-30Updated: 2021-06-03

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

TerminatedNCT02033317

Relypsa, Inc.Hyperkalemia

Start: 2008-08-31End: 2008-12-31Updated: 2021-05-12

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease

CompletedNCT03071263

Relypsa, Inc.Hyperkalemia, Resistant Hypertension

Start: 2017-01-23End: 2018-11-27Updated: 2021-05-12

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

TerminatedNCT03087058

Vifor Pharma, Inc.Hyperkalemia

Start: 2017-07-07End: 2021-04-30Updated: 2022-10-19

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

CompletedNCT03326583

Dominic RajEnd Stage Renal Disease, ESRD, Hyperkalemia

Start: 2017-11-01End: 2020-12-31Updated: 2023-05-09

Exploratory Study of ZG-801 for the Treatment of Hyperkalemia

CompletedNCT03799926

Zeria PharmaceuticalHyperkalemia

Start: 2019-02-18End: 2021-02-02Updated: 2021-03-25

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

RecruitingNCT05766839

Vifor Pharma, Inc.Hyperkalemia

Start: 2025-04-06End: 2030-12-01Target: 32Updated: 2026-06-01

Patiromer for treatment of hyperkalaemia in children from birth to <6 years of age

Active, not recruitingLBCTR2023055223

Vifor Pharma, Inc.Hyperkalaemia hyperkalaemia

Start: 2023-04-17Target: 21Updated: 2026-02-02

Phase 3

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

CompletedNCT01810939

Relypsa, Inc.Chronic Kidney Disease (CKD), Hyperkalemia (HK)

Start: 2013-02-28End: 2013-08-31Updated: 2021-06-03

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

CompletedNCT03888066

Vifor Pharma, Inc.Hyperkalemia

Start: 2019-04-24End: 2021-09-02Updated: 2023-02-24

Phase 4

Patiromer With or Without Food for the Treatment of Hyperkalemia

CompletedNCT02694744

Relypsa, Inc.Hyperkalemia

Start: 2016-02-29End: 2016-08-31Updated: 2021-05-12

Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.

CompletedNCT03183778

NYU Langone HealthChronic Kidney Diseases, Hyperkalemia

Start: 2018-03-12End: 2019-08-01Updated: 2021-12-01

Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer

CompletedNCT03229265

The Rogosin InstituteHyperkalemia, Kidney Transplant

Start: 2017-08-01End: 2019-08-07Updated: 2020-04-13

RELieving Increasing oEdema Due to Heart Failure

TerminatedNCT04142788

NHS Greater Glasgow and ClydeHeart Failure，Congestive

Start: 2020-08-26End: 2022-12-20Updated: 2025-03-04

Comparison of Potassium Binders in the ER

TerminatedNCT04585542

University of California, IrvineAcute Hyperkalemia, Oral Potassium Binders

Start: 2020-10-20End: 2025-01-31Updated: 2026-04-22

Related Papers

Comparative Analysis of Randomized versus Real World Populations in Heart Failure: DIAMOND Trial versus CARE-HK Registry.

2026-05-29

Hyperkalemia management in heart failure and chronic kidney disease: a Spanish cost-effectiveness analysis of patiromer informed by the integrated DIAMOND trial and real-world evidence

BMC Health Services Research2026-04-10

First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting

Journal of Nephrology2024-09-2814 citations

Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia

JACC Heart Failure2024-09-251 citations

Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial

American Journal of Nephrology2024-08-194 citations

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

Nephrology Dialysis Transplantation2024-06-1159 citations

A randomized study to compare oral potassium binders in the treatment of acute hyperkalemia

BMC Nephrology2023-04-0519 citations

Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN

American Journal of Nephrology2023-01-016 citations

A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease

Clinical Kidney Journal2022-10-3086 citations

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial

European Heart Journal2022-07-28194 citations

Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial

Kidney Medicine2021-03-147 citations

Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial

Kidney3602021-01-1518 citations

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.

2019-09-15243 citations

Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.

2018-09-0318 citations

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease

JAMA2015-07-14430 citations

Patiromer Controls RAASi-Associated HK in Patients with Diabetes and CKD

MD Conference Express2015-01-01

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

New England Journal of Medicine2014-11-21647 citations